Semorex Technologies has discovered molecular compounds that exhibit potent and selective anticancer activity against solid tumors and hematological malignancies. The company is interested in using these compounds, which were found to be nontoxic in mice models, to develop anticancer therapies.
Semorex has also developed a diagnostic approach for the rapid and reliable diagnosis of systemic/invasive fungal infection (SFI/IFI). The companys method offers quick and appropriate treatment for patients with fungal infections while ruling out SFI/IFI in individuals suffering from other disease states causing similar symptoms.
Semorex Technologies Ltd is an R&D subsidiary of Semorex Inc.